Pharmaceutical Talent Trends 2026: Building the Workforce of the Future

Talent acquisition, retention, development, and succession planning stay central to staying ahead in pharma, and 2026 brings that into sharper focus. The industry is working through a mix of pressures and openings, shaped by maturing technology, a shifting regulatory picture, and changing expectations from the workforce itself. The shape of the pharma workforce is moving with the demand for advanced skills, the steady embedding of AI into day-to-day work, and a harder look at processes long taken for granted. Broader forces are pulling in the same direction, from an ageing workforce to hybrid models that have now settled into the norm. This article looks at how these trends are landing across the industry, and what companies can do to hold their position over the next few years.

‍

1. The Growing Demand for Highly Specialised Talent

Pharma has always leaned on highly specialised people to drive its science, keep it compliant, and bring new treatments through. In 2026 that demand is sharper, with competition coming from inside and outside the industry, more complex therapeutic areas, and a constant pull towards newer technologies. The pressure to find and keep skilled professionals in clinical trials, regulatory affairs, and pharmacovigilance keeps building, and so does the expectation that these experts adapt quickly to new tools and compliance demands.

One of the harder asks is attracting talent in emerging fields such as cell and gene therapy, personalised medicine, and AI-led drug discovery. As technology works its way deeper into development, companies are investing in upskilling their current people to close the gap between established practice and where the science is heading. The profile employers increasingly want is the "T-shaped" professional, deep in one discipline such as immunology or regulatory science, with broad digital fluency layered on top.

‍

2. Navigating Compliance and Regulatory Change

One of the largest pressures on the industry is keeping pace with a regulatory environment that won't sit still. After a long spell in legislative limbo, the BIOSECURE Act became law in December 2025 as part of the National Defense Authorization Act for fiscal year 2026. Instead of naming specific companies as earlier drafts did, it sets up a list of "biotechnology companies of concern" that restricts federal contracts and grants tied to those suppliers, with the initial list due from the Office of Management and Budget by the end of 2026. For any company with exposure to affected suppliers, that means mapping the supply chain, requalifying partners, and in some cases transferring manufacturing, all of which carries a talent cost in regulatory, quality, and supply functions.

Beyond BIOSECURE, companies still face pressure from the FDA, EMA, and their global counterparts on safety, efficacy, and transparency. With personalised and gene-based therapies becoming more common, and AI now woven through discovery and clinical work, teams have to meet rising standards while keeping development timelines tight. As the rules keep shifting, demand stays high for regulatory affairs professionals who can read the detail and move with it. Compliance talent has to stay current with global standards, risk frameworks, and pharmacovigilance guidance, and training built around these areas is doing a lot of the heavy lifting in keeping companies compliant as they scale.

"The intersection of innovation, such as AI-driven drug development, and the complexities of compliance creates both challenges and opportunities for the industry. To thrive in this environment, organisations must prioritize attracting and developing regulatory professionals who not only understand the nuances of compliance but also excel in leveraging cutting-edge technologies. Companies that build agile, AI-informed regulatory teams will gain a distinct advantage in bringing therapies to market faster while maintaining global standards."

• Audrey Greenberg, Executive, Entrepreneur and Founder of the Centre of Breakthrough Medicine, now part of SK pharmateco.

‍

3. Settling Into Hybrid and Remote Work

The shift to remote and hybrid work that the pandemic forced has stuck, pharma included. Much of the work, especially in R&D and manufacturing, still has to happen hands-on in labs and on production lines, but roles in regulatory affairs, clinical research, medical affairs, and parts of marketing and sales have held onto flexible arrangements through 2026. That flexibility comes with its own demands. Managing distributed teams, keeping collaboration sharp, and holding productivity steady call for different management habits, the right digital tools, and a culture built for it. For some employers, offering genuine flexibility is a clear advantage in attracting strong candidates, though they still have to manage the downsides, from isolation to communication gaps to the security questions that come with sensitive data.

‍

4. Blending Human Expertise and AI

AI and automation are now part of how companies run, not something on the horizon. As demand climbs for skilled people in clinical research, regulatory affairs, and drug development, AI tools are helping ease shortages and lift efficiency. The technology is already established in drug discovery, clinical trials, and talent acquisition itself, and through 2026 it's taking on more of the repetitive load in areas like regulatory compliance. That raises the value of human-AI collaboration rather than lowering it. The "human-in-the-loop" model keeps people across AI-driven processes, so the outputs stay ethical, precise, and grounded in judgement.

The bigger change is in how work is designed. Rather than stacking on extra roles, companies are reengineering workflows so AI and automation sit inside core processes. That brings a challenge with it: getting the balance right between privacy, ethics, and human oversight. There's a lasting need for people to interpret results, confirm compliance, and make the calls that affect patient safety. As the technology advances, the priority is making sure teams have the knowledge and skills to use AI well at work.

‍

5. Upskilling and Retaining Talent

With more of the work running on advanced technology, continuous learning is what keeps pharma professionals competitive. Upskilling and reskilling sit near the top of the priority list, so teams are ready for new tools, regulatory shifts, and changing market demands. That means investing in training that builds technical and regulatory skills alongside the softer ones, leadership, and the adaptability the industry runs on.

Retention asks for something similar. Holding onto strong people starts with treating candidate experience as the foundation of a longer relationship. A good experience sets the tone for someone's time with the company and feeds directly into whether they stay.

‍

Conclusion: Building the Pharma Workforce of the Future

Through 2026 the industry is already living the shifts in regulation and compliance, driven by political, economic, and commercial pressures. Those changes call for more agile, better-informed teams who can handle complexity across the whole of drug development, from R&D to market approval. Global regulators, shaped by new public health priorities and faster-moving technology, are setting stricter standards and tighter review timelines. To stay ahead, companies need a workforce that can read these external forces early and adapt, holding compliance steady while still bringing therapies to patients faster.

The commercial picture is pushing in the same direction. Stronger competition in emerging therapeutic areas and continued pressure on pricing and market access are moving teams towards cross-functional work and longer-range planning. The wave of manufacturing investment now landing in the US, with reshoring commitments running into the hundreds of billions and major new facilities announced across the sector, is adding fresh demand for advanced manufacturing, engineering, and quality talent. The workforce that meets all this has to pair deep technical expertise with commercial judgement.

‍

Building it takes a few things at once:

Investing in talent development. Upskilling and reskilling have to keep pace with new technology, regulatory change, and market shifts, and the training should cover leadership and adaptability as much as technical skill.

Embracing diversity and inclusion. A diverse workforce sharpens thinking and decision-making, which matters in an industry this globally connected. More women are moving into senior roles, but they remain underrepresented at executive level, so there's still work to do.

Leveraging technology and AI. As AI reshapes pharma operations, companies have to balance automation with human oversight, and equip teams to use it ethically and well.

Promoting flexibility. Hybrid and remote models, handled with care, can draw strong talent while supporting better work-life balance and productivity.

Pharma has always driven new science, even if it's never been the fastest industry to react. The workforce coming through will carry that forward if the industry is going to keep thriving. By getting ahead of the regulatory, technological, and talent challenges, companies can build resilient teams that are ready to lead rather than play catch-up. The next few years will set the tone for the industry, and the organisations putting real investment into their people, processes, and technology are the ones that will come out in front, in patient care and in global health.

If you're looking for a talent partner with expertise in the industry to help you grow this year, get in touch to learn more about our embed, search and learn solutions.